Skip to main content
Hefei Lifeon Pharmaceutical Co., Ltd. logo

Hefei Lifeon Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 003020 ISIN · CNE100004BD9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 751 across all filing types
Latest filing 2026-05-18 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 003020

About Hefei Lifeon Pharmaceutical Co., Ltd.

https://www.lifeon.cn

Hefei Lifeon Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on therapeutic areas including cardiovascular and cerebrovascular diseases, anti-infectives, and metabolic disorders. A key component of its portfolio is Clopidogrel Hydrogen Sulfate, an antiplatelet agent used for stroke and heart attack prevention. The organization operates advanced production facilities compliant with Good Manufacturing Practice (GMP) standards and maintains a strong commitment to technological innovation. Its research and development efforts are directed toward high-quality generic medications and the exploration of innovative drug delivery systems to address complex clinical requirements.

Recent filings

Filing Released Lang Actions
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is titled “2025年年度股东会决议公告” and details the convening, attendance, proposals, and precise voting outcomes of the annual shareholders’ meeting (AGM). It discloses resolutions passed, vote counts, and percentages, matching the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). There is no substantive financial report or presentation; it purely publishes shareholder vote results.
2026-05-18 Chinese
安徽天禾律师事务所关于合肥立方制药股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 81% confidence The document is a legal opinion letter issued by a law firm regarding the convening, attendance, procedures, and voting results of the company’s 2025 annual general meeting. It is not the AGM presentation itself (AGM-R), nor a shareholder solicitation (PSI), nor a pure voting results announcement by the company (DVA). Rather, it is a compliance/legal filing confirming that the AGM procedures and outcomes comply with relevant laws and the company’s articles. Therefore, it falls under the general Regulatory Filings (RNS) category.
2026-05-18 Chinese
关于2025年度利润分配及资本公积金转增股本预案的公告
Notice of Dividend Amount Classification · 85% confidence The document is a regulatory “临时公告” detailing the company’s 2025 profit distribution plan: the cash dividend per 10 shares (RMB 3.00) and the capital reserve conversion into bonus shares (2 shares per 10). It is not a full annual report or audit report, nor a voting result notice, but rather an announcement of dividend payment details (including bonus share issues). Accordingly, it best fits the “Notice of Dividend Amount” category (DIV).
2026-04-27 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2026年第一季度报告" which translates to "2026 First Quarter Report". It contains detailed financial statements including consolidated balance sheet, profit and loss statement, and cash flow statement for the first quarter of 2026. The document also includes management declarations about the accuracy and completeness of the quarterly report, and notes that the report is unaudited. The presence of comprehensive financial data for a period shorter than a full fiscal year (quarterly) and detailed financial analysis confirms this is an Interim / Quarterly Report. It is not an announcement or a brief summary but the full quarterly report itself, exceeding 5,000 characters and containing substantive financial data. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2026
2026-04-27 Chinese
非经营性资金占用及其他关联资金往来情况专项说明
Audit Report / Information Classification · 90% confidence The document is a special audit report issued by Zhonghui CPA firm on non-operating fund usage and related party transactions for Hefei Lifang Pharmaceutical Co., Ltd. It includes management and auditor responsibilities, scope, and a special audit opinion, followed by audited summary tables. This is a standalone audit report and not a full annual or interim report. It matches the definition of an Audit Report / Information (AR).
2026-04-27 Chinese
关于聘请2026年度财务审计机构的公告
Regulatory Filings Classification · 78% confidence The document is a formal public announcement by a listed company regarding the proposed appointment (re-appointment) of its external auditor for the next fiscal year. It does not itself contain an audit report (AR), nor is it a financial report (10-K, IR) or proxy/material for shareholder voting (PSI). It is not a board or management change announcement (MANG) since it concerns auditor engagement, and it is not covered by any other more specific category. Therefore, under the fallback “Regulatory Filings” category, the correct classification is RNS.
2026-04-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.